托伐普坦治疗慢性重度心衰的疗效研究  

Study on the Efficacy of Tolvaptan in the Treatment of Chronic Severe Heart Failure

作　　者：史汇江 SHI Hui-jiang(Department of Cardiovascular Medicine,Yixing Fourth People's Hospital,Yixing,Jiangsu Province,214200 China)

机构地区：[1]宜兴市第四人民医院心血管内科,江苏宜兴214200

出　　处：《中外医疗》2021年第1期115-117,共3页China & Foreign Medical Treatment

摘　　要：目的对托伐普坦治疗慢性重度心衰的疗效进行分析。方法随机选择2018年1月—2019年12月间该院收治的获得临床确诊的慢性重度心衰患者40例作为研究对象,按照治疗方法,分成观察组与对照组,每组20例。对照组采用抗心衰药物规范化治疗,观察组患者在对照组基础上,增加托伐普坦治疗。对两组患者的治疗效果进行对比分析,观察指标包括心功能改善情况、用药24 h内尿量情况、心脏彩色多普勒测定结果等。结果治疗后观察组心功能改善有效率为95.0%,对照组为65.0%,观察组高于对照组,差异有统计学意义(χ^(2)=3.906,P<0.05);患者在用药24 h内,观察组患者尿量发生显著增加,差异有统计学意义(t=9.772,P<0.05);治疗后,两组患者左室舒张末期内径水平比较,差异无统计学意义(P>0.05),观察组左室射血分数显著高于对照组,差异有统计学意义(P<0.05)。结论针对慢性重症心衰患者,应用托伐普坦进行治疗,效果显著,可有效改善患者心功能,及时纠正低钠低氯血症,临床价值明显。Objective To analyze the efficacy of tolvaptan in the treatment of chronic severe heart failure.Methods From January 2018 to December 2019,40 patients with chronic severe heart failure who were clinically diagnosed in the hospital were randomly selected as the research objects.According to the treatment method,they were divided into observation group and control group,with 20 cases in each group.The control group was treated with standardized anti-heart failure drugs,and the observation group was treated with tolvaptan on the basis of the control group.The treatment effects of the two groups of patients were compared and analyzed.The observation indicators included the improvement of cardiac function,the urine output within 24 hours of medication,and the results of cardiac color Doppler measurement.Results After treatment,the effective rate of cardiac function improvement in the observation group was 95.0%,and that of the control group was 65.0%,which was higher than that in the control group,the difference was statistically significant(χ^(2)=3.906,P<0.05);within 24 hours of treatment,the urine output of the observation group increased significantly,the difference was statistically significant(t=9.772,P<0.05);After treatment,there was no significant difference in the left ventricular end-diastolic diameter between the two groups(P>0.05).The left ventricular ejection fraction of the observation group was significantly higher than that of the control group,the difference was statistically significant(P<0.05).Conclusion For patients with chronic severe heart failure,the application of tolvaptan has a significant effect.It can effectively improve the heart function of patients and correct hyponatremia and hypochloremia in time.It has obvious clinical value.

关 键 词：托伐普坦 慢性重度心衰 治疗 神经内分泌因子 临床应用 

分 类 号：R541.6[医药卫生—心血管疾病]